title: Could NAMPT inhibition become a potential treatment option in hepatocellular carcinoma?
authors.affiliation: a Institute of Metabolism and Systems Research, College of Medical and Dental Sciences , University of Birmingham , Birmingham , UK.|c Center for Pediatric Research, Hospital for Children and Adolescents , Leipzig University , Leipzig , Germany.
authors.forename: Antje
authors.initials: A
authors.lastname: Garten
authors.affiliation: b Department of Pediatrics , University of California San Diego , La Jolla , CA , USA.|c Center for Pediatric Research, Hospital for Children and Adolescents , Leipzig University , Leipzig , Germany.
authors.forename: Susanne
authors.initials: S
authors.lastname: Schuster
authors.affiliation: c Center for Pediatric Research, Hospital for Children and Adolescents , Leipzig University , Leipzig , Germany.
authors.forename: Melanie
authors.initials: M
authors.lastname: Penke
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000201:enzymology; D016207:Cytokines / Q000037:antagonists & inhibitors*; D015195:Drug Design; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D054409:Nicotinamide Phosphoribosyltransferase / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D016207:Cytokines; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human
keywords: APO866; CHS-828; FK866; GMX1778; Hepatocarcinoma; NAD; Sorafenib; nicotinamide phosphoribosyltransferase; resistance; sirtuin